| 2026-08-21 17:17 |
8-K |
["3.01"] |
other |
0.05
|
Nasdaq delisting notice due to insufficient stockholders' equity; no M&A signal. |
SEC · detail |
| 2026-08-17 07:17 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine 8-K filing with Q2 2026 earnings press release; no M&A signals detected. |
SEC · detail |
| 2026-08-13 17:25 |
8-K |
["5.02", "8.01"] |
officer change |
0.45
|
CEO and CFO departures contingent on stockholder approval; board restructuring planned but no M&A language. |
SEC · detail |
| 2026-08-10 21:13 |
8-K |
["9.01"] |
merger agreement |
0.98
|
ADIL completed acquisition of Azora Therapeutics per merger agreement dated June 11, 2026; 8-K/A amends to include required financial statements. |
SEC · detail |
| 2026-06-11 12:43 |
8-K |
["1.01", "5.03"] |
merger agreement |
0.99
|
ADIL completed acquisition of Azora Therapeutics via merger agreement dated June 11, 2026, issuing stock and preferred shares to Azora stockholders. |
SEC · detail |
| 2026-05-11 08:40 |
8-K |
["2.02", "9.01"] |
other |
0.05
|
Routine Q1 2026 earnings release with no M&A signals, strategic review, or transaction language. |
SEC · detail |